Millendo Therapeutics, Inc. (MLND)
|Net Income (ttm)||-36.41M|
|Trading Day||May 12|
|Day's Range||1.00 - 1.07|
|52-Week Range||0.92 - 3.64|
NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: ht...
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Mi...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therape...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
NEW YORK, April 2, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...
Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeut...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair t...
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics mo...
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics and Tempest Therapeutics announce a proposed merger agreement.
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.
There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reassessed the s...
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with sig...
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.
As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.
Millendo Therapeutics: A Forgotten Biotech With Strong Potential
Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wedbush.
It’s not that unusual in the world of biotech and emerging medtech to run across companies that have previously never been heard of or covered.
Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
|Stock Exchange |
|Ticker Symbol |
According to 3 analysts, the average rating for MLND stock is "Hold." The 12-month stock price forecast is 2.00, which is an increase of 98.02% from the latest price.